Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-04
2005-01-04
Weber, Jon P. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C435S068100
Reexamination Certificate
active
06838432
ABSTRACT:
A method for inhibiting and for reversing the dysfunctional response of vascular endothelial cells to an inflammatory stimulus in a subject in need of such therapy has been developed in which an effective amount of a pharmaceutical composition comprising thrombin-activatable fibrinolysis inhibitor (TAFI) combined with a pharmaceutically acceptable carrier and optionally other treatments is administered to the subject.
REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4992373 (1991-02-01), Bang et al.
patent: 5993815 (1999-11-01), Bajzar et al.
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6159468 (2000-12-01), Carlson et al.
patent: 20020147229 (2002-10-01), Allerton et al.
patent: 20020177560 (2002-11-01), Greenfield et al.
Bajzar, “Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway,” Arterioscler. Thromb. Vasc. Biol. 20(12): 2511-2518 (2000).
Boffa, et al., “Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B),” Biochemistry 38(20): 6547-6558 (1999).
Campbell, et al., “Inactivation of C3a and C5a octapeptides by carboxypeptides R and carboxypeptidase N,” Microbiol. Immunol. 46(2): 131-134 (2002).
Collard, et al. “Complement activation after oxidative stress. Role of the lectin complement pathway,” Am. J. Pathol. 156: 1549-1556 (2000).
Daugherty, et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,” Nucl. Acids Res. 19(9): 2471-2476 (1991).
Gross, et al., “CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain,” Thromb. Haemost. 77(5): 894-900 (1997).
Henry, et al., “Identification of Polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled,” Blood 97(7): 2053-2058 (2001).
Laudes, et al., “Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis,” Am. J. Path. 160(5): 1867-1875 (2002).
Laedley, et al., “Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents,” J. Pharmacol. Toxicol. Methods 43(2): 101-116 (2000).
Leavell, et al., “The role of fibrin degradation products in neutrophil recruitment to the lung,” Am. J. Respir. Cell. Mol. Biol. 14: 53-60 (1996).
Nesheim, et al., “Myocardinal infarction and the balance between fibrin deposition and removal,” Ital. Heart 2(9): 641-645 (2001).
Pereira, et al., “Human procarboxypeptidase B: Three-dimensional structure antimplications for thrombin-activatable fibrinolysis inhibitor,” J. Mol. Biol. 321(3): 537-547 (2002).
Riedmemann, et al., “Increased C5a receptor expression in sepsis,” J. Clin. Invest. 110(1): 101-108 (2002).
Taylor, et al., “Protein C prevents the coagulopathic and lethal effects ofEscherichia coliinfusion in the baboon,” J. Clin. Invest. 79: 918-925 (1987).
Watanabe, et al., “Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation,” Thromb. Res. 104: 1-6 (2001).
Baxter Healthcare, Inc, “Protein C,”www.protein.com/proteinc/generallags.
Bajzar Laszlo
Taylor, Jr. Fletcher B.
Audet Maury
Holland & Knight LLP
McMaster University
Oklahoma Medical Research Foundation
Weber Jon P.
LandOfFree
Treatment of sepsis with TAFI does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of sepsis with TAFI, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of sepsis with TAFI will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374913